These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24986094)

  • 21. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial.
    Nelson HS; Gross NJ; Levine B; Kerwin EM; Rinehart M; Denis-Mize K;
    Clin Ther; 2007 Oct; 29(10):2167-78. PubMed ID: 18042473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers.
    Cassella JV; Spyker DA; Yeung PP
    Int J Clin Pharmacol Ther; 2015 Nov; 53(11):963-71. PubMed ID: 26501204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycopyrronium for inhalation. COPD: another antimuscarinic with cardiac adverse effects that require monitoring.
    Prescrire Int; 2014 Feb; 23(146):36-9. PubMed ID: 24669382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
    de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
    Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of intravenous zanamivir on cardiac repolarization.
    Lou Y; Gan J; Peppercorn A; Gould E; Weller S; Piscitelli SC; Patel P
    Pharmacotherapy; 2013 Jul; 33(7):701-9. PubMed ID: 23553534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of cimetidine, a model drug for inhibition of the organic cation transport (OCT2/MATE1) in the kidney, on the pharmacokinetics of glycopyrronium.
    Dumitras S; Sechaud R; Drollmann A; Pal P; Vaidyanathan S; Camenisch G; Kaiser G
    Int J Clin Pharmacol Ther; 2013 Oct; 51(10):771-9. PubMed ID: 24040847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A thorough QT study of guanfacine.
    Martin P; Satin L; Kahn RS; Robinson A; Corcoran M; Purkayastha J; Youcha S; Ermer JC
    Int J Clin Pharmacol Ther; 2015 Apr; 53(4):301-16. PubMed ID: 25109412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
    Dahl R; Chapman KR; Rudolf M; Mehta R; Kho P; Alagappan VK; Chen H; Banerji D
    Respir Med; 2013 Oct; 107(10):1558-67. PubMed ID: 23867808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients.
    Fogarty C; Hattersley H; Di Scala L; Drollmann A
    Respir Med; 2011 Mar; 105(3):337-42. PubMed ID: 21144724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
    Mehta R; Green M; Patel B; Wagg J
    J Pharmacokinet Pharmacodyn; 2016 Apr; 43(2):153-64. PubMed ID: 26739997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD).
    Sechaud R; Renard D; Zhang-Auberson L; Motte Sde L; Drollmann A; Kaiser G
    Int J Clin Pharmacol Ther; 2012 Feb; 50(2):118-28. PubMed ID: 22257577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes.
    Böttcher M; Düngen HD; Corcea V; Donath F; Fuhr R; Gal P; Mikus G; Trenk D; Coenen M; Pires PV; Maschke C; Aliprantis AO; Besche N; Becker C
    Am J Cardiovasc Drugs; 2023 Mar; 23(2):145-155. PubMed ID: 36633816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers.
    Wang Z; Grasela DM; Krishna G
    Clin Ther; 2007 Jun; 29(6):1098-106. PubMed ID: 17692724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials.
    Harris SC; Morganroth J; Ripa SR; Thorn MD; Colucci S
    Postgrad Med; 2017 Jan; 129(1):69-80. PubMed ID: 27927048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization.
    Chen S; Min SS; Peppercorn A; Borland J; Lou Y; Song I; Fujiwara T; Piscitelli SC
    Pharmacotherapy; 2012 Apr; 32(4):333-9. PubMed ID: 22422361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach.
    Bartels C; Looby M; Sechaud R; Kaiser G
    Br J Clin Pharmacol; 2013 Dec; 76(6):868-79. PubMed ID: 23506208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers.
    Shumaker RC; Zhou M; Ren M; Fan J; Martinez G; Aluri J; Darpo B
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1109-17. PubMed ID: 24658627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase 1, double-blind, 4-period crossover study to investigate the effects of pomalidomide on QT interval in healthy male subjects.
    Mondal SA; Assaf M; Liu L; O'Mara E
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):251-8. PubMed ID: 26754679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers.
    Peeters M; Janssen K; Kakuda TN; Schöller-Gyüre M; Lachaert R; Hoetelmans RM; Woodfall B; De Smedt G
    Ann Pharmacother; 2008 Jun; 42(6):757-65. PubMed ID: 18445705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models.
    Pulido-Rios MT; McNamara A; Obedencio GP; Ji Y; Jaw-Tsai S; Martin WJ; Hegde SS
    J Pharmacol Exp Ther; 2013 Aug; 346(2):241-50. PubMed ID: 23685545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.